Teacher Retirement System of Texas Takes $462,000 Position in Repligen Co. (RGEN)

Teacher Retirement System of Texas bought a new position in shares of Repligen Co. (NASDAQ:RGEN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 12,727 shares of the biotechnology company’s stock, valued at approximately $462,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of RGEN. SG Americas Securities LLC acquired a new stake in shares of Repligen during the 3rd quarter worth about $180,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Repligen during the 3rd quarter worth about $241,000. Brown Advisory Inc. acquired a new stake in shares of Repligen during the 3rd quarter worth about $310,000. First Manhattan Co. lifted its stake in shares of Repligen by 16.7% during the 4th quarter. First Manhattan Co. now owns 10,500 shares of the biotechnology company’s stock worth $380,000 after buying an additional 1,500 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan lifted its stake in shares of Repligen by 74.7% during the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 14,060 shares of the biotechnology company’s stock worth $539,000 after buying an additional 6,010 shares during the last quarter. Institutional investors own 87.60% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of analysts have recently issued reports on RGEN shares. BidaskClub cut shares of Repligen from a “hold” rating to a “sell” rating in a research note on Wednesday, February 7th. Citigroup started coverage on shares of Repligen in a research note on Friday, December 8th. They set a “buy” rating and a $45.00 target price for the company. JPMorgan Chase & Co. assumed coverage on shares of Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 target price for the company. Zacks Investment Research cut shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 24th. Finally, TheStreet upgraded shares of Repligen from a “c” rating to a “b-” rating in a research note on Tuesday. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $44.38.

Shares of Repligen Co. (RGEN) opened at $36.75 on Friday. Repligen Co. has a 12 month low of $29.56 and a 12 month high of $46.81. The company has a quick ratio of 8.08, a current ratio of 9.63 and a debt-to-equity ratio of 0.17. The firm has a market cap of $1,587.06, a PE ratio of 51.76, a price-to-earnings-growth ratio of 2.44 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The business had revenue of $41.60 million during the quarter, compared to analysts’ expectations of $41.13 million. During the same quarter in the previous year, the company earned $0.08 EPS. The business’s revenue was up 62.5% on a year-over-year basis. equities analysts expect that Repligen Co. will post 0.7 earnings per share for the current fiscal year.

In other Repligen news, Director Thomas F. Ryan, Jr. sold 4,696 shares of Repligen stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $36.16, for a total value of $169,807.36. Following the completion of the sale, the director now owns 9,700 shares in the company, valued at approximately $350,752. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Anthony Hunt sold 8,970 shares of Repligen stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the completion of the sale, the chief executive officer now owns 83,613 shares of the company’s stock, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Teacher Retirement System of Texas Takes $462,000 Position in Repligen Co. (RGEN)” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/03/17/teacher-retirement-system-of-texas-takes-462000-position-in-repligen-co-rgen.html.

Repligen Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply